复旦张江(688505) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was CNY 185,132,977, a decrease of 58.40% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2023 was CNY 21,454,125, down 70.53% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 16,582,241, a decline of 75.58% compared to the previous year[5] - Basic earnings per share for Q3 2023 were CNY 0.02, a decrease of 71.43% from the same period last year[7] - Total operating revenue for the first three quarters of 2023 was CNY 707,960,683, a decrease of 1.4% compared to CNY 716,265,980 in the same period of 2022[22] - Net profit for the first three quarters of 2023 reached CNY 89,811,290, significantly increasing from CNY 36,739,951 in the same period of 2022, representing a growth of 144.5%[23] - Basic and diluted earnings per share for the third quarter of 2023 were both CNY 0.09, compared to CNY 0.04 in the same quarter of 2022, reflecting a 125% increase[24] - The company reported a total comprehensive income of CNY 89,646,489 for the first three quarters of 2023, compared to CNY 35,535,491 in the same period of 2022[24] Research and Development - The total R&D investment for Q3 2023 was CNY 50,730,733, down 28.58% year-on-year, representing 27.40% of operating revenue[7] - Research and development expenses for the first three quarters of 2023 were CNY 168,541,486, slightly down from CNY 171,893,365 in the previous year[22] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was CNY 1,712,208, down 99.13% compared to the previous year[5] - Cash flow from operating activities for the first three quarters of 2023 was CNY 1,712,208, a notable recovery from CNY 196,182,795 in the previous year[26] - The net cash flow from investing activities was -$35,490,426, an improvement from -$79,977,072 in the previous year[27] - Total cash and cash equivalents at the end of the period amounted to $1,242,462,297, slightly up from $1,237,143,906 year-over-year[27] - Cash inflow from financing activities was $66,861,642, compared to no inflow in the same quarter last year[27] - Cash outflow for financing activities totaled $80,030,878, down from $88,302,716 in the previous year[27] - The net increase in cash and cash equivalents was -$46,840,367, contrasting with a positive increase of $28,262,995 in the same quarter last year[27] - The company reported a cash outflow of $74,615,047 for dividend payments, which is an increase from $72,030,000 in the previous year[27] - The cash flow from investment activities showed a total outflow of $3,091,638,335, compared to $2,940,247,379 last year[27] Assets and Liabilities - The total assets at the end of Q3 2023 were CNY 2,946,016,262, a decrease of 1.01% from the end of the previous year[7] - As of September 30, 2023, the total assets of Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. amounted to CNY 2,946,016,262, a decrease from CNY 2,976,007,272 at the end of 2022[18][20] - The total current assets were CNY 1,950,086,202, down from CNY 2,069,188,785 in the previous year[18] - The company's cash and cash equivalents stood at CNY 1,242,462,297, compared to CNY 1,289,302,664 at the end of 2022[18] - Total liabilities decreased to CNY 609,240,398 from CNY 722,985,917 in the previous year[20] - The total equity attributable to shareholders increased to CNY 2,335,669,182 from CNY 2,257,102,217[20] - The company reported a net profit of CNY 899,575,888 in retained earnings, slightly up from CNY 882,244,301[20] - The company’s inventory increased to CNY 41,127,892 from CNY 40,526,760[18] - The long-term equity investments decreased to CNY 295,000,545 from CNY 305,767,001[19] - The company’s short-term borrowings were CNY 100,000,000, a slight decrease from CNY 101,000,000[19] - The company’s total liabilities to equity ratio improved, reflecting a stronger equity position[20] Shareholder Information - The company has a total of 22,420 common shareholders as of the end of the reporting period[13] Other Financial Metrics - The weighted average return on equity for Q3 2023 was 0.92%, a decrease of 2.43 percentage points year-on-year[7] - The company experienced a credit impairment loss of CNY -30,928,727 in the third quarter of 2023, compared to CNY -22,666,224 in the same quarter of 2022[23] - Other income for the first three quarters of 2023 was CNY 5,547,249, an increase from CNY 2,481,052 in the previous year[22] - The company has not adopted new accounting standards or interpretations for the current year[27]